Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roderick S Tang

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Journal of Virology|September 29, 2004
Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeysRoderick S Tang, Mia MacPhail, Jeanne H Schickli, et al.
Plos One|November 9, 2013
Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of ageElissa Malkin, Ram Yogev, Nazha Abughali, et al.
The Journal of General Virology|May 29, 2004
Identification of small-animal and primate models for evaluation of vaccine candidates for human metapneumovirus (hMPV) and implications for hMPV vaccine designMia MacPhail, Jeanne H Schickli, Roderick S Tang, et al.
Journal of Virology|September 27, 2003
Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicityRoderick S Tang, Jeanne H Schickli, Mia MacPhail, et al.
The Journal of Clinical Investigation|March 10, 2015
Palivizumab epitope-displaying virus-like particles protect rodents from RSV challengeJeanne H Schickli, David C Whitacre, Roderick S Tang, et al.
Vaccine|September 30, 2008
Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adultsRoderick S Tang, Richard R Spaete, Mark W Thompson, et al.
The Journal of General Virology|December 4, 2003
Evaluation of attenuation, immunogenicity and efficacy of a bovine parainfluenza virus type 3 (PIV-3) vaccine and a recombinant chimeric bovine/human PIV-3 vaccine vector in rhesus monkeysSridhar Pennathur, Aurelia A Haller, Mia MacPhail, et al.
Journal of Virology|July 16, 2004
Recovery of human metapneumovirus genetic lineages a and B from cloned cDNASander Herfst, Miranda de Graaf, Jeanne H Schickli, et al.
Vaccine|February 12, 2005
A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeysRoderick S Tang, Kutubuddin Mahmood, Mia Macphail, et al.
NPJ Vaccines|July 29, 2022
Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2Mariana F Tioni, Robert Jordan, Angie Silva Pena, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Journal of Virology|September 29, 2004
Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeysRoderick S Tang, Mia MacPhail, Jeanne H Schickli, et al.
Plos One|November 9, 2013
Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of ageElissa Malkin, Ram Yogev, Nazha Abughali, et al.
The Journal of General Virology|May 29, 2004
Identification of small-animal and primate models for evaluation of vaccine candidates for human metapneumovirus (hMPV) and implications for hMPV vaccine designMia MacPhail, Jeanne H Schickli, Roderick S Tang, et al.
Journal of Virology|September 27, 2003
Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicityRoderick S Tang, Jeanne H Schickli, Mia MacPhail, et al.
The Journal of Clinical Investigation|March 10, 2015
Palivizumab epitope-displaying virus-like particles protect rodents from RSV challengeJeanne H Schickli, David C Whitacre, Roderick S Tang, et al.
Vaccine|September 30, 2008
Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adultsRoderick S Tang, Richard R Spaete, Mark W Thompson, et al.
The Journal of General Virology|December 4, 2003
Evaluation of attenuation, immunogenicity and efficacy of a bovine parainfluenza virus type 3 (PIV-3) vaccine and a recombinant chimeric bovine/human PIV-3 vaccine vector in rhesus monkeysSridhar Pennathur, Aurelia A Haller, Mia MacPhail, et al.
Journal of Virology|July 16, 2004
Recovery of human metapneumovirus genetic lineages a and B from cloned cDNASander Herfst, Miranda de Graaf, Jeanne H Schickli, et al.
Vaccine|February 12, 2005
A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeysRoderick S Tang, Kutubuddin Mahmood, Mia Macphail, et al.
NPJ Vaccines|July 29, 2022
Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2Mariana F Tioni, Robert Jordan, Angie Silva Pena, et al.
Pageof 3